Microtubule-interacting drugs for cancer treatment

Trends in Pharmacological Sciences

Volumn 24, Issue 7, 2003, Pages 361-365

  Checchi, Paula M ^a,b   Nettles, James H ^b   Zhou, Jun ^a,b   Snyder, James P ^b   Joshi, Harish C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AROYLINDOLE; 2 METHOXY 5 (2,3,4 TRIMETHOXYPHENYL)TROPONE; 2 METHOXYESTRADIOL; A 204197; ANTINEOPLASTIC AGENT; CEMADOTIN; COLCHICINE; CRYPTOPHYCIN DERIVATIVE; DICOUMAROL; DISCODERMOLIDE; EPOTHILONE A; EPOTHILONE B; ESTRAMUSTINE; INDANOCINE; LAULIMALIDE; NAVELBINE; NOSCAPINE; PACLITAXEL; PELORUSIDE A; PODOPHYLLOTOXIN; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIVISION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; MICROTUBULE; MICROTUBULE ORGANIZING CENTER; MITOSIS; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; MICROTUBULES; MITOSIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0042233662     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00161-5     Document Type: Review

References (57)

1. Shibuya K., et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 26:2002;2-37.
2. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1:2001;222-231.
3. Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science. 297:2002;559-565.
4. Jallepalli P.V., Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat. Rev. Cancer. 1:2001;109-117.
5. Stewart Z.A., et al. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24:2003;139-145.
6. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science. 287:2000;1969-1973.
7. Wood K.W., et al. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1:2001;370-377.
8. Drukman S., Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents. Int. J. Oncol. 21:2002;621-628.
9. Kavallaris M., et al. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Updat. 4:2001;392-401.
10. Nogales E. Structural insights into microtubule function. Annu. Rev. Biochem. 69:2000;277-302.
11. Valiron O., et al. Microtubule dynamics. Cell. Mol. Life Sci. 58:2001;2069-2084.
12. Desai A., Mitchison T.J. Microtubule polymerization dynamics. Annu. Rev. Cell Dev. Biol. 13:1997;83-117.
13. Margolis R.L., Wilson L. Microtubule treadmilling: what goes around comes around. BioEssays. 20:1998;830-836.
14. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev. Biol. 16:2000;89-111.
15. Jordan M.A., Wilson L. The use and action of drugs in analyzing mitosis. Methods Cell Biol. 61:1999;267-295.
16. Jordan A., et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18:1998;259-296.
17. Correia J.J., Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. 13:2001;1213-1228.
18. Leoni L.M., et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J. Natl. Cancer Inst. 92:2000;217-224.
19. Schumacher G., Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J. Cancer Res. Clin. Oncol. 127:2001;405-410.
20. Tahir S.K., et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61:2001;5480-5485.
21. Beckers T., et al. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res. 62:2002;3113-3119.
22. Ngan V.K., et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 60:2000;5045-5051.
23. Panda D., et al. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10560-10564.
24. Jordan M.A., et al. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 37:1998;17571-17578.
25. Shih C., Teicher B.A. Cryptophycins: a novel class of potent antimitotics antitumor depsipeptides. Curr. Pharm. Des. 7:2001;1259-1276.
26. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48:1997;353-374.
27. Nogales E., et al. High-resolution model of the microtubule. Cell. 96:1999;79-88.
28. Snyder J.P., et al. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5312-5316.
29. Lillo M.P., et al. Location and properties of the taxol binding center in microtubules: a picosecond laser study with fluorescent taxoids. Biochemistry. 41:2002;12436-12449.
30. Altaha R., et al. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr. Pharm. Des. 8:2002;1707-1712.
31. Altmann K.H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr. Opin. Chem. Biol. 5:2001;424-431.
32. He L., et al. Novel molecules that interact with microtubules and have functional activity similar to Taxol™ Drug Discov. Today. 6:2001;1153-1164.
33. Kowalski R.J., et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52:1997;613-622.
34. Giannakakou P., Fojo T. Discodermolide: just another microtubule- stabilizing agent? No! A lesson in synergy. Clin. Cancer Res. 6:2000;1613-1615.
35. Madari H., et al. Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res. 63:2003;1214-1220.
36. Pryor D.E., et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moeity for activity. Biochemistry. 41:2002;9109-9115.
37. Hood K.A., et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res. 62:2002;3356-3360.
38. Ye K., et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1601-1606.
39. Zhou J., et al. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J. Biol. Chem. 277:2002;17200-17208.
40. Landen J.W., et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 62:2002;4109-4114.
41. 2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem. 277:2002;39777-39785.
42. Ke Y., et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune response. Cancer Immunol. Immunother. 49:2000;217-225.
43. Zhou J., et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol. 63:2003;799-807.
44. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR, and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:2000;265-283.
45. Bosch I., Croop J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophysa. Acta Mol. Cell Res. 1288:1996;37-54.
46. Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? J. Natl. Cancer Inst. 95:2003;255-257.
47. Min/+ mice. Cancer Res. 63:2003;895-901.
48. Wu H., et al. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63:2003;1515-1519.
49. Giannakakou P., et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
50. Gonzalez-Garay M.L., et al. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J. Biol. Chem. 274:1999;23875-23882.
51. Giannakakou P., et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2904-2909.
52. Cowan N.J., Dudley L. Tubulin isotypes and the multigene tubulin families. Int. Rev. Cytol. 85:1983;147-173.
53. Joshi H.C., Cleveland D.W. Diversity among tubulin isotypes: toward what functional end? Cell Motil. Cytoskeleton. 16:1990;159-163.
54. Roach M.C., et al. Preparation of a monoclonal antibody specific for the class I isotype of β-tubulin: the β isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil. Cytoskeleton. 39:1998;273-285.
55. Burkhart C.A., et al. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta. 1471:2001;1-9.
56. Kavallaris M., et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61:2001;5803-5809.
57. Nicoletti M.I., et al. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin. Cancer Res. 7:2001;2912-2922.